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Cisplatin is one of themost commonly used anticancer drugs. It kills
cancer cells by damaging their DNA, and hence cellular DNA repair
capacity is an important determinant of its efficacy. Here, we inves-
tigated the repair of cisplatin-induced DNA damage in mouse liver
and testis tissue extracts prepared at regular intervals over the
course of a day. We find that the XPA protein, which plays an
essential role in repair of cisplatin damage by nucleotide excision
repair, exhibits circadian oscillation in the liver but not in testis.
Consequently, removal of cisplatin adducts in liver extracts, but
not in testis extracts, exhibits a circadian pattern with zenith at
∼5 pm and nadir at ∼5 am. Furthermore, we find that the circadian
oscillation of XPA is achieved both by regulation of transcription by
the core circadian clock proteins including cryptochrome and by
regulation at the posttranslational level by the HERC2 ubiquitin
ligase. These findings may be used as a guide for timing of cis-
platin chemotherapy.
chemotherapy ∣ circadian clock ∣ DNA repair
Chronochemotherapy is the administration of chemotherapeu-tic drugs at specific times of the day so as to optimize efficacy
and minimize side effects of the drug (1, 2). Cisplatin is one of the
three most commonly used chemotherapeutic drugs (3) for which
chronotherapy is thought to have some beneficial effects. Factors
that modulate the efficacy of cisplatin therapy include drug up-
take and efflux, DNA adduct formation, DNA repair, and cellular
proliferation (4, 5). Cisplatin produces DNA intra- and inter-
strand diadducts and DNA–protein crosslinks (4), and it is well
established that the intrastrand diadducts Pt-(GpG), Pt-(ApG),
and Pt-(GpXpG), that constitute up to 90% of the total DNA
lesions, are the main cause of its cytotoxicity and hence its ther-
apeutic effects. These lesions are removed exclusively by nucleo-
tide excision repair (excision repair) in mammalian cells and
hence the status of excision repair is an important factor in the
success of chemotheraphy with cisplatin (4, 6).
In humans and mice, excision repair is carried out by the co-
ordinated action of six core repair factors, RPA, XPA, XPC,
TFIIH, XPG, and XPF-ERCC1, which remove the damage in the
form of 24–32 nt-long oligomers; the resulting gap is filled by
DNA polymerases and ligated (7–9).
Recently, we found that the rate of excision repair of a UV
photoproduct in the mouse brain exhibits a daily rhythm (10).
Furthermore, it appears that this rhythmic pattern is due to
the circadian (circa ¼ about, dies ¼ day) oscillation of the XPA
(xeroderma pigmentosum A) protein that is one of the rate-
limiting factors in excision repair. Even though in that study
the damaged-DNA substrate was a UV photoproduct, we sug-
gested that the findings were relevant to the repair of cisplatin
because nucleotide excision repair is the only repair system capa-
ble of removing bulky DNA lesions produced by UV or by UV-
mimetic agents such as cisplatin (11). Although cisplatin is used
for treating certain brain cancers, the blood–brain barrier is a
serious impediment for its general use in brain tumors (12). In
contrast, cisplatin is the drug of choice in testicular and ovarian
cancers and a main component of combination therapy regimens
for many other cancers, including head and neck, lung, gastric,
and colorectal cancers (3). Therefore, in this study we have tested
the effect of the circadian clock on the repair capacity of
cisplatin–DNA adducts in peripheral organs with the aim of pro-
viding a guide for cisplatin chronochemotheraphy. We chose
mouse liver and testis for our experiments for practical reasons,
because extracts from these organs are of relatively good quality
for biochemical assays. We find that excision repair of cisplatin–
DNA adducts in mouse liver exhibits a robust circadian rhythm
with the zenith in the late afternoon hours (∼5 pm) and the nadir
in the early morning hours (∼5 am). We further show that this
oscillation is caused by the circadian rhythmicity of Xpa transcrip-
tion and translation, coupled with a short half-life of the protein.
In contrast, in the testis, which is known to lack a circadian
rhythm (13–15), Xpa transcription, XPA protein levels, and exci-
sion activity remained constant and at a moderately high level
over the course of the day.
The circadian clock in mice and humans is generated by a
transcriptional-translational feedback loop: The Clock and
BMal1 transcriptional activators bind to the promoters of
Cryptochrome 1 and 2 (Cry1/2) and Period 1 and 2 (Per1/2) repres-
sor genes and activate their transcription. The Cry and Per pro-
teins, in turn, enter the nucleus after a time lag, bind to Clock and
BMal1, and inhibit their own transcription as well as the tran-
scription of clock-controlled output genes (16). This core clock
circuitry is consolidated by secondary feedback loops at the tran-
scriptional level as well as by posttranslational modifications and
proteolytic degradation of the core clock proteins. In particular,
the ubiquitination of Cry proteins by Fbxl3 (17–19) and of Per
proteins by βTRCP (20, 21) and subsequent proteolysis of these
transcriptional repressors by the proteasome are essential for a
robust core clock as well as robust oscillations of the clock-
controlled genes.
We and others previously reported that the XPA protein and
transcript (and the excision repair activity for UV photoproducts)
were controlled by the circadian clock in the mouse brain (10, 22).
Here, we have directly measured the Xpa transcript levels in the
liver and testis and found that Xpa mRNA exhibits circadian
rhythm in liver, and this oscillation is dependent on the circadian
clock. In addition, since solely altering the transcription of a gene
may not be sufficient to confer an oscillatory mode for its activity
profile unless the gene product has a relatively short lifetime, we
determined the half-life of XPA protein in cultured cells and
found it to be similar to those of Cry1/2 that are known to be
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processed specifically by Fbxl3 ubiquitin ligase. We reasoned that
XPA may also be a target of a specific E3 ligase. We found that
the HERC2 protein that, based on sequence data, is classified as
a putative E3 ligase of the HECTclass (23), binds specifically to
XPA and ubiquitinates it. Importantly, downregulation ofHERC2
leads to stabilization of XPA and increased repair activity of cis-
platin damage in cultured cells. Similarly, in Cry1/2 double knock-
out mice (CryDKO), the Xpa transcript and protein levels cease to
oscillate, and the liver extracts exhibit high levels of cisplatin ex-
cision activity at all tested time points. In contrast, Cry mutations
have no effect onXpa transcript and protein levels in the testis and
hence no effect on cisplatin repair activity over the course of the
day. Taken together, our study provides somemechanistic founda-
tion for cisplatin chronochemotherapy for the vast majority of or-
gans that contain a strong circadian regulatory component.
Results
Effect of Circadian Time on Excision Repair of Cisplatin–DNA Adducts
by Mouse Liver Extracts.Cisplatin, and its second and third genera-
tion derivatives, make two major DNA adducts, Pt-(GpG) and Pt-
(GpTpG), in addition to the much less frequent G-Pt-G inter-
strand crosslink (3). Extensive data indicate that the intrastrand
diadducts are the major cause of cytotoxicity and that nucleotide
excision repair is the sole repair system for these adducts (4).
Further, even though the Pt-(GpG) adduct is more abundant than
the Pt-(GpTpG) adduct, the latter is repaired at about fivefold
faster rate than Pt-(GpG) (7, 24). Therefore, we used either lin-
ear or circular DNA molecules containing a single Pt-(GpTpG)
to assess the repair capacity of mouse tissue extracts. Fig. 1 shows
the excision assays conducted with mouse liver extracts harvested
at 4 h intervals over a period of 24 h (ZT0 light on and ZT12 light
off for mice maintained under 12 h light: 12 h dark schedule). As
apparent from the primary data in Fig. 1A and B and the quan-
titative analysis in Fig. 1C, the repair of cisplatin-(GpTpG) and
the Xpa transcript and protein levels exhibited robust and in-
phase daily oscillation in the liver. Moreover, the phases of these
oscillations were antiphase to the clock transcriptional repressor
Cry1 and in synchrony with those of excision activity and XPA
oscillation previously reported in mouse brain (10). Also, as pre-
viously demonstrated with the mouse brain extracts, supplement-
ing the liver extracts from the nadir of excision activity (ZT22 or
5 am) with recombinant XPA, restored the level of excision repair
to that observed at the zenith (ZT10 or 5 pm) (Fig. 1D).
To ascertain that the circadian oscillation of XPA level and ex-
cision repair were dependent on the circadian clock, we analyzed
liver extracts from wild-type mice or mice lacking Cry1 and Cry2
(25, 26), essential components of the circadian clock (16). Anal-
ysis of excision repair activity from liver extracts harvested at the
zenith (ZT10) or nadir (ZT22) revealed that the excision repair
activity was three times higher in CryDKO mice compared to the
zenith of wild-type mice and did not oscillate with the time of day
(Fig. 1E). Likewise, the XPA protein and mRNA levels were
higher in the CryDKO mice and did not oscillate (Fig. 1F). There-
fore, the oscillation of excision repair activity and Xpa mRNA
and protein levels in the mouse liver are all dependent on the
circadian clock.
Effect of Circadian Time on Excision Repair of Cisplatin-DNA Adducts
by Mouse Testis. Next, we tested extracts made from mouse testis
harvested at 4 h intervals over a 24 h period. In contrast to the
results obtained with liver, repair of cisplatin-(GpTpG) did not
exhibit daily oscillation in the testis (Fig. 2A and C). To determine
the cause of this lack of oscillatory behavior in testis we measured
the expression of XPA and the clock protein Cry1, which is known
to oscillate in most tissues, over the course of a day. As shown in
Fig. 2B and C, neither XPA nor Cry1 oscillate in testis. These
findings are consistent with several reports on lack of the circa-
dian clock either at the transcriptional or protein level in the
mouse testis (13–15). Interestingly, because of lack of circadian
control of Xpa transcription in the testis, excision repair activity is
at a constitutively high level, and neither repair (Fig. 2D) nor the
level of XpamRNA and protein (Fig. 2E) are affected by the pre-
sence or absence of the Cry proteins.
XPA Protein Has a Short Lifetime. The findings that XPA exhibits
high amplitude oscillation in the mouse brain (10) and liver
(Fig. 1C), reaching a maximum in the afternoon and dropping
precipitously at night with a 5- to 10-fold decrease in protein level
within a 6-h period at night, was of special interest. We reasoned
that such a drop could not be ascribed to clock-controlled tran-
scriptional oscillation alone, and that XPA might be controlled at
a posttranslational level as well. Hence, we tested XPA for pro-
teolytic degradation using human (A549) and rat (Rat1) cell lines
that are commonly used in cell biology and circadian clock re-
search as representative of human and rodent cells, respectively.
Fig. 1. Circadian oscillation of Xpa transcript, XPA protein, and nucleotide
excision repair activity in the mouse liver. Mice under 12 h light: 12 h dark
(L12∶D12) cycle were sacrificed at the indicated times and their livers were
harvested. Zeitgeber ðZTÞ ¼ 0 is light on and ZT ¼ 12 is light off. In parenth-
eses we also indicate the time of day in conventional Eastern Standard Time
(EST). The liver extracts were tested for repair activity and for the indicated
protein and mRNA levels. (A) The control lane contained DNA substrate but
no extract. The excision products [indicated as a bar with a circle (isotope la-
beled) and a triangle (Pt adduct)] in the range of 24–32 nt were detected by
autoradiography (48) (Fig. S1). Only the part of the autoradiograph contain-
ing the excision product is shown; the entire gel is shown in Fig. S2. (B) Xpa
mRNA and protein were detected by RT-PCR and immunoblotting, respec-
tively. (C) The excision repair datapoints are averages of two experiments
each with two mice (bars ¼ standard error). The mRNA, protein, and repair
levels are plotted relative to the maximum values of each (which happen to
be at ZT ¼ 10). The actual amount of excision at ZT10 was 1.8%. (D) Liver
extracts from ZT22 (nadir of repair activity) were supplemented with increas-
ing amounts of XPA (0.25, 0.5, 1 pmol of XPA) and the excision activity in the
supplemented extracts are plotted relative to that of the activity of ZT10
(zenith) extract. (E and F) Liver extracts prepared at the indicated ZTs from
wild-type or Cry1/2 double knockout mice (CryDKO) were analyzed for exci-
sion repair activity (E) and XPA and Cry proteins and mRNAs (F). The CryDKO
extracts contained 2.4- and 2.3-fold more XPA protein and mRNA relative to
the ZT10 of WT, respectively.








The two cell lines were treated with either cycloheximide (CHX)
to inhibit protein synthesis or with MG132 to inhibit proteolysis
by the proteosome, and then the XPA levels were measured for a
6 h period following treatment. As is seen in Fig. 3A, inhibition of
protein synthesis by CHX (lanes 2–4) leads to a steady drop in
XPA levels in both cell lines, whereas there is no change in the
control protein Actin over the course of the experiment. In
contrast, when MG132 is included in the culture medium to in-
hibit proteolysis, the levels of XPA steadily increased in both
cell lines (lanes 5–7). Quantitative analysis of the data (Fig. 3B)
shows that XPA decays with a first-order rate constant of k1 ∼ 6×
10−5 sec−1 from which a half-life of t1∕2 ∼ 200 min is calculated,
which is in accord with the rapid drop in XPA protein levels in the
brain and liver in the evening hours when the XPA gene transcrip-
tion is rapidly declining as well, such that the proteolytically de-
graded XPA cannot be replenished by newly synthesized protein.
Specific Interaction of XPA with a Putative Ubiquitin Ligase.Next, we
wished to identify the ubiquitin ligase that ubiquitinates XPA and
targets it for proteolysis. We constructed a HEK293 cell line that
contains an inducible and Flag epitope-tagged XPA gene. Cell
extract was prepared from Flag-XPA expressing cells and XPA
was immunoprecipitated with anti-Flag agarose resin. After
extensive washing, the bound proteins were eluted with Flag pep-
tide and separated by SDS–PAGE (Fig. 4A). The proteins that
were specifically retained by the Flag-XPA resin were identified
by mass spectrometry. The highest molecular weight protein
identified in our screen was HERC2. This is a putative HECT E3
ligase and a member of a six-member HERC family that has been
implicated in a number of cellular processes including G-protein
signaling and membrane trafficking (23). Naturally occurring
Herc2 mutations cause the so-called rjs (runty, jerky, sterile) phe-
notype in mice (27), but there have been no cellular or biochem-
ical studies reported on HERC2 indicative of its E3 ligase activity.
Hence, we proceeded to look at the XPA-HERC2 interaction in
more detail and to determine the effect of HERC2 on XPA mod-
ification and stability.
Fig. 2. Circadian clock-independent repair of cisplatin-(GpTpG) adducts in
mouse testis. Testicular extracts were prepared from mice under L12∶D12
conditions and were tested for repair activity with the cisplatin-(GpTpG) sub-
strate (A) and for the indicated protein and mRNA levels (B). (C) The excision
repair data points are averages of two experiments (bars ¼ standard error).
The mRNA, protein, and repair values are expressed in percentages relative
to the ZT10 values. The actual amount of excision at ZT10 was 7.8%. (D) Ex-
tracts prepared at the indicated times from testes of either wild-type or
CryDKO mice were analyzed for excision repair activity, and the percentages
of excised products are indicated below the lanes. (E) The proteins were de-
tected by probing immunoblots with the indicated antibodies and the mRNA
levels were analyzed by RT-PCR.
Fig. 3. Degradation of XPA by the proteasome in human and mouse cell
lines. (A) Immunoblots of extracts from A549 and Rat1 cells that were treated
with either 20 μg∕ml of protein synthesis inhibitor cycloheximide (CHX) or
40 μM proteosome inhibitor (MG132) for the indicated times. Whole cell ly-
sates were separated by SDS-PAGE and probed with the appropriate antibo-
dies. (B) The amounts are expressed relative to the control samples (time 0)
which were taken immediately before the addition of either CHX or MG132.
Fig. 4. Interaction of XPA with the putative ubiquitin E3 ligase HERC2.
(A) HEK293 cells stably expressing either Flag-tagged XPA or Flag-tagged
RAD1 (control) were induced to express the corresponding proteins. The cell
lysates were then mixed with anti-Flag agarose beads and the bound pro-
teins were visualized by SDS-PAGE and SYPRO Ruby staining. The XPA-
interacting proteins were identified by mass spectroscopy. For clarity, we in-
dicate only the bands corresponding to XPA, HERC2, and DNA-PKcs (which
migrates like a doublet of HERC2). (B) XPA was immunoprecipitated from ex-
tract of either Flag-XPA or mock (control) expressing cells with anti-Flag
beads and the unbound and bound fractions were probed with the appro-
priate antibodies. The input lanes contain 5% of the input protein. (C) Two
cell lines were fractionated into “cytosol,” “nuclear,” and “chromatin” frac-
tions and the distribution of XPA, HERC2, HERC1, and markers for the three
subcellular fractions GAPDH (cytosolic), ORC2 (nuclear), H2A.X (chromatin)
were analyzed by immunoblotting. (D) 293T and A549 cells were permea-
blized, fixed, stained with XPA and either HERC1 or HERC2 antibodies
(Fig. S6), and imaged using a fluorescent microscope.
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First, we investigated the XPA-HERC2 interaction specificity
by immunoprecipitating XPA and probing the immunoprecipitate
for HERC2, as well as for proteins known to interact with XPA
(RPA70 and RPA32) (28) and proteins that are not expected to
interact with XPA (HERC1, MDM2, and ACTIN). The results
are shown in Fig. 4B. As expected, XPA binds tightly to RPA such
that under the conditions of the experiment, where XPA is over-
produced 22-fold over the endogenous levels, nearly 90% of RPA
is in a complex with XPA (compare lanes 3 and 4). Significantly,
while neither MDM2 nor ACTIN is detected in the XPA immu-
noprecipitate (lane 6), about 40% of HERC2 is immunoprecipi-
tated with anti-Flag antibodies (compare lanes 3, 4, and 6). We
further confirmed the XPA-HERC2 interaction by coimmuno-
precipitating endogenous HERC2 with anti-XPA antibodies in
A549 cells (Fig. S3).
Second, because the other members of the HERC family of
putative E3 ligases that have been investigated so far are asso-
ciated with membrane or cytoplasmic organelles (29), and XPA
is primarily located in the nucleus (30), we wished to ascertain
whether XPA and HERC2 have similar subcellular localization
to allow interaction between the two and ubiquitination of
XPA. We analyzed the subcellular localization of the two proteins
by biochemical and cell biological methods using two human cell
lines. Fig. 4C shows the results of the subcellular fractionation. In
agreement with previous reports (30), XPA is found mostly in the
nuclear fraction (Fig. 4C, lanes 2 and 5). The small fraction of
XPA that is found in the cytosol is most likely the result of
incidental permeabilization of the nuclear membrane during frac-
tionation. Importantly, while HERC1, which is known to be as-
sociated with the Golgi complex and endoplasmic reticulum (29)
exhibits exclusively cytosolic localization, HERC2 shows nearly
equal distribution between the cytosol and the nuclear fractions
(Fig. 4C, lanes 1 and 2, and 4 and 5). These conclusions were
confirmed by immunostaining. In agreement with the subcellular
fractionation data, HERC1 is exclusively cytoplasmic, XPA is ex-
clusively nuclear, and HERC2 exhibits both cytoplasmic and nu-
clear localization (Fig. 4D). Taken together, the data presented so
far show that XPA is an unstable protein, colocalizes with a pu-
tative ubiquitin ligase, and appears to directly interact with this
ligase, suggesting that HERC2 may be responsible for directing
the proteolysis of XPA and thus participating in its circadian os-
cillatory expression pattern.
HERC2 is an Ubiquitin Ligase for XPA and Promotes its Proteolysis. To
determine whether HERC2 influences the stability of XPA, we
downregulated HERC2 or HERC1 with siRNA and measured
the levels of XPA in the siRNA treated cells. As is seen in Fig. 5A,
downregulation of HERC2 (lane 7), but not HERC1 (lane 6),
stabilizes XPA after cycloheximide (CHX) treatment. Fig. 5B
shows the XPA degradation kinetics under conditions of CHX
treatment in the presence or absence of HERC2 siRNA. In
the absence of HERC2 siRNA, XPA is degraded with kinetics si-
milar to that shown in Fig. 3, whereas in the presence of HERC2
siRNA and CHX, the XPA levels essentially remain constant for
the duration of the experiment (8 h). Because XPA is not the only
limiting factor in nucleotide excision repair (31), we also analyzed
the effect ofHERC2 downregulation on the other core repair fac-
tors and found that these proteins were not affected by CHX
treatment or by CHX treatment combined with HERC2 siRNA
over a period of 8 h (Fig. S4A). We also tested for the effect of
HERC2 on some of the key DNA damage checkpoint proteins
because they also affect the cellular response to genotoxic agents
and again, did not see an effect of HERC2 downregulation on
these proteins either (Fig. S4B). Thus, it appears that, of all the
excision repair and checkpoint proteins tested, HERC2 plays a
role only in proteolysis of XPA and as a consequence in circadian
oscillation of excision repair activity.
The data presented so far indicate that HERC2 may
ubiquitinate XPA and thus target it for proteolytic degradation,
but there are no reports on the E3 ligase activity of HERC2.
Therefore, to test our model, we conducted an ubiquitination
assay with HERC2 using XPA as a substrate. HERC2 was
immunoprecipitated from A549 cells and, after extensive wash-
ing, the immunoprecipitate was supplemented with E1, E2, HA-
tagged ubiquitin (HA-Ub) and Flag-XPA under appropriate re-
action conditions. The products were separated by SDS–PAGE
and probed with either Flag or ubiquitin antibodies. As seen
in Fig. 5C, when supplemented with E1 and E2, the immunopre-
cipitated HERC2 does ubiquitinate XPA (lane 4) and hence it is
possibly a bona fide E3 ubiquitin ligase. HERC2 also ubiquiti-
nates itself or another interacting protein in these reactions
(Fig. S5).
Downregulation of HERC2 Improves Cisplatin-(GpG) Repair Efficiency.
Our data indicate that XPA is a limiting factor in nucleotide ex-
cision repair in vivo, and therefore we wished to know whether
increasing XPA levels by inhibition of ubiquitination and proteo-
lytic degradation of XPA would manifest in a faster rate of repair
of cisplatin–DNA adducts. HEK293 cells that were transfected
with either control siRNA orHERC2 siRNA were incubated with
either 10 μM or 30 μM cisplatin for 3 h, and then the drug was
removed from the medium and the Pt-(GpG) excision kinetics
were determined by DNA slot blot using monoclonal antibodies
specific for this adduct. As seen in Fig. 6A and B, downregulation
of HERC2 results in a faster rate of Pt-(GpG) repair, supporting
the conclusion that in tissues or cell lines with a circadian clock,
the rate of nucleotide excision repair is controlled by ubiquitina-
tion of XPA by HERC2 E3 ligase. In line with this conclusion,
even in a cell culture where each cell has a circadian rhythm
but the culture on the whole is without a circadian rhythm be-
cause the circadian phases of the cells are out of synchrony (2),
overexpression of XPA even in the presence of HERC2 leads to a
modest but significant increase in excision activity (Fig. 6C) be-
cause apparently under these conditions the rate of XPA synthe-
sis far exceeds the rate of ubiquitination by HERC2.
Discussion
Our findings, in light of current knowledge about the molecular
mechanism of the circadian clock, are schematically summarized
in Fig. S8. In wild-type mice, oscillatory transcription of the clock
genes (Crys and Pers) and the clock-controlled gene Xpa, com-
bined with the action of E3 ligases specific for the respective
proteins, engender the core circadian clock and the oscillation
Fig. 5. Identification of HERC2 as an XPA ubiquitin ligase. (A) 293Tcells were
transfected with control Cyclophilin-B siRNA (C), HERC1 siRNA (H1), HERC2
siRNA (H2), or both HERC1 andHERC2 siRNAs (H1/2), and then incubated with
cycloheximide (CHX) where indicated and the levels of the target proteins as
well as of XPA and GAPDH (loading control) were determined by immuno-
blotting. (B) Control CycP-B orHERC2 siRNA treated cells were incubated with
CHX for the indicated times and the levels of the HERC2, XPA, control pro-
teins, and GAPDH were determined by immunoblots. (C) A549 cell extract
was incubated with Protein A agarose and either HERC2 antibodies or control
rabbit IgG. The beads were collected and incubated with the indicated pro-
teins at 30 ºC for 30 minutes followed by separation on SDS–PAGE and anal-
ysis by western blotting with either Flag antibodies for XPA (Top) or with
ubiquitin antibodies (Bottom).








of one of the clock output pathways, nucleotide excision repair,
respectively. In the absence of Crys, there is no circadian clock,
XPA is expressed at constitutively high levels, and the excision
repair activity is elevated and ceases to oscillate. The data pre-
sented in this paper raise some important points relevant to
the regulation of nucleotide excision repair in mammals and the
evolution of the circadian clock, and are of potential significance
to rational approaches to chronochemotherapy.
Regulation of Nucleotide Excision Repair. Our study has defined a
relatively direct pathway for regulation of nucleotide excision re-
pair in mice and humans. To recapitulate briefly, we find that
XPA is regulated in a circadian manner in all mouse tissues
tested, with the exception of testis. We show that oscillation of the
XPA protein is accomplished by two mechanisms: 1) trans-
criptional regulation by cryptochrome and other core clock pro-
teins, and 2) proteolysis by the ubiquitin (HERC2 E3 ligase)-
proteasome pathway. Our findings of circadian clock control of
XPA, and of excision repair activity in brain and liver, constitute
the most direct evidence to date of any form of control of nucleo-
tide excision repair activity. Although numerous studies have
shown that both the core excision repair factor XPC and the
accessory factor XPE (DDB2) are ubiquitinated by the
CUL4A-ROC1-DDB1 E3 ubiquitin ligase following DNA da-
mage (32–34), at present it is unclear what effects these
posttranslational modifications have on excision repair (35). The
ubiquitination of XPC does not lead to its proteolytic degrada-
tion, and it is unclear whether it affects its function (36). Ubiqui-
tination of DDB2 leads to its eventual proteolytic degradation
(33). However, it is a matter of ongoing debate whether
DDB2 plays a direct role in repair or influences cell survival di-
rectly or indirectly by participating in apoptosis and cell cycle reg-
ulation (34, 37–40). In contrast, the findings reported in this
paper clearly show that XPA is controlled by transcriptional
and posttranslational mechanisms, and that the oscillatory
rhythm of the protein resulting from these regulatory mechan-
isms has a drastic effect on the repair capacity of the cell. Hence,
in studies on excision repair capacity in animals and even mam-
malian cell lines, with the aim of determining the effects of var-
ious parameters, such as genetic background, race, gender, and
age, on excision repair rate, the time of day (or circadian time) of
sampling or assay should be considered as an important variable.
Cryptochrome, “Escape from Light,” and Evolution of the Circadian
Clock. Cryptochrome, which is a key component of the circa-
dian clock, phylogenetically is related to DNA photolyase, which
repairs UV-induced pyrimidine photodimers using blue light as
the energy source (41). According to the modern version of the
“Escape from Light” hypothesis for the evolution of the circa-
dian clock (41, 42), an ancient aquatic organism employed the
photolyase/cryptochrome ancestor as a blue-light sensor (crypto-
chrome) to regulate its diel vertical movements so as to optimize
nutrient availability and minimize exposure to genotoxic UV
light, and as a blue-light activated repair enzyme (photolyase)
that repairs UV damage that inevitably occurs despite the pre-
sence of an escape from light mechanism. Subsequently, during
evolution, this protoenzyme gave rise to the present day crypto-
chrome, which is strictly a clock protein, and photolyase, which is
strictly a repair enzyme. It is rather remarkable, therefore, that
cryptochrome still participates in repair, albeit indirectly, by reg-
ulating the nucleotide excision repair activity in mice and
humans. In these organisms, which lack photolyase, nucleotide
excision repair is the sole repair mechanism for removing UV-
induced dipyrimidine photoproducts that can also be repaired
by the phylogenetic relative of cryptochrome, photolyase, in other
organisms such as fruit flies (41).
Whether circadian control of nucleotide excision repair con-
fers a selective advantage or is an evolutionary relic cannot be
answered based on available data. It is conceivable that even noc-
turnal animals such as mice are exposed to sunlight that produces
DNA damage, and therefore the continuous rise in excision re-
pair activity during the day serves a useful purpose. Conversely, it
might be advantageous to reduce the excision repair activity at
night, when it apparently is not needed, so as to reduce the risk
of attack of normal DNA by this repair system (“gratuitous
repair”) that may cause deleterious mutations (43, 44). In this
regard, it is interesting to note that UvrA, the key damage recog-
nition protein in E. coli nucleotide excision repair, in a manner
similar to XPA, is also tightly regulated by proteolysis so as to
avoid gratuitous repair and harmful mutagenesis (45).
Chronochemotherapy.The daily oscillation of excision repair activ-
ity is likely to affect the efficacy of chemotherapy with certain
drugs. Cisplatin and its second and third generation derivatives
are among the most commonly prescribed anticancer drugs (3).
With the development of new derivatives that have better uptake,
activation, and DNA binding properties, the range of cancers that
are treated with cisplatin is continuously expanding (3). However,
despite the many improvements in cancer treatment regimens
that have increased the efficacy and decreased the side effects of
the drug, the time of administration, which may significantly af-
fect both the efficacy and the side effects (toxicity), has not
become a commonly used variable in clinical practice (2). This
Fig. 6. Downregulation of HERC2 improves cisplatin-(GpG) repair efficiency.
(A) A549 cells in which either Cyclophilin-B (C) or HERC2 (H2) were downre-
gulated by siRNA were treated with the indicated doses of cisplatin for
3 hours, washed, and then incubated in fresh medium for the indicated times
before harvesting. The Pt-(GpG) diadduct levels were analyzed by immuno-
blotting (Left) and SYBR-Gold staining of the membrane showing total DNA
in the slot blot (Right). (B) Quantitative analysis of the data from Panel A. (C)
Extracts were made from circadian asynchronous cultures of HEK293 cells or
HEK293 cells overexpressing Flag-XPA 22-fold higher than the endogenous
protein levels and used in excision assays with cisplatin-(GpTpG) substrate.
Each lane represents an independent experiment. The effect on excision re-
pair is not proportional to the level of XPA overexpression because under
these conditions other excision repair factors become rate-limiting.
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is due in part to the lack of a mechanistic foundation for the roles
of circadian factors in chemotherapy.
The cellular response to genotoxic agents is dictated by several
factors (46, 47), including the cell cycle phase, DNA repair capac-
ity, and potential for apoptosis. Hence, in designing a chrono-
chemotheraphy regimen, all these factors must be taken into
account. Here we show that in mouse liver, excision repair of cis-
platin adducts exhibits a robust circadian oscillatory pattern, with
a maximum at ∼5 pm and a minimum at ∼5 am. These findings
should be useful in designing mechanism-based chronochem-
otherapy trials in mice and eventually in humans.
Materials and Methods
Organ Harvesting and Preparation of Cell-Free Extracts. Cell-free extracts (CFEs)
from C57BL/6J mice and Cry1-/-Cry2-/- mice in the same background (26) were
prepared as described previously (10) with modifications. See SI Text
for details.
Excision Assay. Linear (140 bp) or circular (2.9 kbp) substrates containing a
single Pt-(GpTpG) adduct were prepared by established methods and the ex-
cision assay was carried out with 10 fmol of substrate and 100 μg of CFE in
25 μl excision buffer by incubating at 30 °C for 1 h. See SI Text for details.
In Vivo Excision Repair Assay. A monoclonal antibody which recognizes Pt-
(GpG) adducts (49) (Oncolyze) was used in a slot blot assay to quantify the
adduct levels in the DNA of cisplatin treated A549 cells as a function of time.
See SI Text for details.
Immunoblotting, RT-PCR, and siRNA. See SI Methods for details.
Subcellular Fractionations and Immunofluorescence. See SI Methods for details.
Proteomics and Ubiquitination Assay. See SI Methods for details.
ACKNOWLEDGMENTS. We thank Michael Kemp for providing recombinant
RPA and for critical reading of the manuscript, and Drs. Kenneth Kreuzer
(Duke University), Bennett Van Houten (University of Pittsburgh), and Peng-
bo Zhou (Cornell University) for useful comments on the manuscript. This
work was supported by National Institutes of Health Grants GM31082 and
GM32833.
1. Kobayashi M, Wood PA, Hrushesky WJ (2002) Circadian chemotherapy for gyneco-
logical and genitourinary cancers. Chronobiol Int 19:237–251.
2. Levi F, Schibler U (2007) Circadian rhythms: Mechanisms and therapeutic implications.
Annu Rev Pharmacol Toxicol 47:593–628.
3. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev
Cancer 7:573–584.
4. Jung Y, Lippard SJ (2007) Direct cellular responses to platinum-induced DNA damage.
Chem Rev 107:1387–1407.
5. Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM (2008) The role of cellular
accumulation in determining sensitivity to platinum-based chemotherapy. Annu
Rev Pharmacol Toxicol 48:495–535.
6. Chaney SG, Sancar A (1996) DNA repair: Enzymatic mechanisms and relevance to drug
response. J Natl Cancer Inst 88:1346–1360.
7. Sancar A (1996) DNA excision repair. Annu Rev Biochem 65:43–81.
8. Reardon JT, Sancar A (2005) Nucleotide excision repair. Prog Nucleic Acid Res Mol Biol
79:183–235.
9. Wood RD (1997) Nucleotide excision repair in mammalian cells. J Biol Chem
272:23465–23468.
10. Kang TH, Reardon JT, Kemp M, Sancar A (2009) Circadian oscillation of nucleotide
excision repair in mammalian brain. Proc Natl Acad Sci USA 106:2864–2867.
11. Kang TH, Sancar A (2009) Circadian regulation of DNA excision repair: implications for
chrono-chemotherapy. Cell Cycle 8:1665–1667.
12. Johnsson A, et al. (1995) Pharmacokinetics and tissue distribution of cisplatin in nude
mice: Platinum levels and cisplatin-DNA adducts. Cancer Chemother Pharmacol
37:23–31.
13. Miyamoto Y, Sancar A (1999) Circadian regulation of cryptochrome genes in the
mouse. Brain Res Mol Brain Res 71:238–243.
14. Morse D, Cermakian N, Brancorsini S, Parvinen M, Sassone-Corsi P (2003) No circadian
rhythms in testis: Period1 expression is clock independent and developmentally regu-
lated in the mouse. Mol Endocrinol 17:141–151.
15. Lambert CM, Weaver DR (2006) Peripheral gene expression rhythms in a diurnal
rodent. J Biol Rhythms 21:77–79.
16. Reppert SM, Weaver DR (2002) Coordination of circadian timing in mammals. Nature
418:935–941.
17. Busino L, et al. (2007) SCFFbxl3 controls the oscillation of the circadian clock by direct-
ing the degradation of cryptochrome proteins. Science 316:900–904.
18. Godinho SI, et al. (2007) The after-hours mutant reveals a role for Fbxl3 in determining
mammalian circadian period. Science 316:897–900.
19. Siepka SM, et al. (2007) Circadian mutant Overtime reveals F-box protein FBXL3
regulation of cryptochrome and period gene expression. Cell 129:1011–1023.
20. Reischl S, et al. (2007) Beta-TrCP1-mediated degradation of PERIOD2 is essential for
circadian dynamics. J Biol Rhythms 22:375–386.
21. Shirogane T, Jin J, Ang XL, Harper JW (2005) SCFbeta-TRCP controls clock-dependent
transcription via casein kinase 1-dependent degradation of the mammalian period-1
(Per1) protein. J Biol Chem 280:26863–26872.
22. Hughes M, et al. (2007) High-resolution time course analysis of gene expression from
pituitary. Cold Spring Harb Sym 72:381–386.
23. Rotin D, Kumar S (2009) Physiological functions of the HECT family of ubiquitin ligases.
Nat Rev Mol Cell Biol 10:398–409.
24. Huang JC, Zamble DB, Reardon JT, Lippard SJ, Sancar A (1994) HMG-domain proteins
specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin
by human excision nuclease. Proc Natl Acad Sci USA 91:10394–10398.
25. Vitaterna MH, et al. (1999) Differential regulation of mammalian period genes and
circadian rhythmicity by cryptochromes 1 and 2. Proc Natl Acad Sci USA
96:12114–12119.
26. Selby CP, Thompson C, Schmitz TM, Van Gelder RN, Sancar A (2000) Functional redun-
dancy of cryptochromes and classical photoreceptors for nonvisual ocular photorecep-
tion in mice. Proc Natl Acad Sci USA 97:14697–14702.
27. Lehman AL, et al. (1998) A very large protein with diverse functional motifs is deficient
in rjs (runty, jerky, sterile) mice. Proc Natl Acad Sci USA 95:9436–9441.
28. Wold MS (1997) Replication protein A: A heterotrimeric, single-stranded DNA-binding
protein required for eukaryotic DNA metabolism. Annu Rev Biochem 66:61–92.
29. Garcia-Gonzalo FR, Rosa JL (2005) The HERC proteins: Functional and evolutionary
insights. Cell Mol Life Sci 62:1826–1838.
30. Miyamoto I, Miura N, Niwa H, Miyazaki J, Tanaka K (1992) Mutational analysis of the
structure and function of the xeroderma pigmentosum group A complementing pro-
tein. Identification of essential domains for nuclear localization and DNA excision re-
pair. J Biol Chem 267:12182–12187.
31. Kesseler KJ, Kaufmann WK, Reardon JT, Elston TC, Sancar A (2007) A mathematical
model for human nucleotide excision repair: Damage recognition by random order
assembly and kinetic proofreading. J Theor Biol 249:361–375.
32. Sugasawa K, et al. (2005) UV-induced ubiquitylation of XPC protein mediated by
UV-DDB-ubiquitin ligase complex. Cell 121:387–400.
33. El-Mahdy MA, et al. (2006) Cullin 4A-mediated proteolysis of DDB2 protein at DNA
damage sites regulates in vivo lesion recognition by XPC. J Biol Chem
281:13404–13411.
34. Liu L, et al. (2009) CUL4A abrogation augments DNA damage response and protection
against skin carcinogenesis. Mol Cell 34:451–460.
35. Bergink S, Jentsch S (2009) Principles of ubiquitin and SUMO modifications in DNA
repair. Nature 458:461–467.
36. Wang QE, et al. (2005) DNA repair factor XPC is modified by SUMO-1 and ubiquitin
following UV irradiation. Nucleic Acids Res 33:4023–4034.
37. Itoh T, Cado D, Kamide R, Linn S (2004) DDB2 gene disruption leads to skin tumors and
resistance to apoptosis after exposure to ultraviolet light but not a chemical carcino-
gen. Proc Natl Acad Sci USA 101:2052–2057.
38. Hanawalt PC, Spivak G (2008) Transcription-coupled DNA repair: Two decades of
progress and surprises. Nat Rev Mol Cell Biol 9:958–970.
39. Hwang BJ, Ford JM, Hanawalt PC, Chu G (1999) Expression of the p48 xeroderma
pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc
Natl Acad Sci USA 96:424–428.
40. Stoyanova T, Roy N, Kopanja D, Bagchi S, Raychaudhuri P (2009) DDB2 decides cell fate
following DNA damage. Proc Natl Acad Sci USA 106:10690–10695.
41. Sancar A (2004) Regulation of the mammalian circadian clock by cryptochrome. J Biol
Chem 279:34079–34082.
42. Gehring W, Rosbash M (2003) The coevolution of blue-light photoreception and
circadian rhythms. J Mol Evol 57(Suppl 1):S286–289.
43. Branum ME, Reardon JT, Sancar A (2001) DNA repair excision nuclease attacks
undamaged DNA. A potential source of spontaneous mutations. J Biol Chem
276:25421–25426.
44. Hasegawa K, Yoshiyama K, Maki H (2008) Spontaneous mutagenesis associated with
nucleotide excision repair in Escherichia coli. Genes Cells 13:459–469.
45. Pruteanu M, Baker TA (2009) Controlled degradation by ClpXP protease tunes the
levels of the excision repair protein UvrA to the extent of DNA damage.Mol Microbiol
71:912–924.
46. Beland FA, Dooley KL, Sheldon WG, Delongchamp RR (1988) Circadian variation in
the induction of intestinal tumors by N-methyl-N-nitrosourea in male C57BL/6N mice.
J Natl Cancer Inst 80:325–330.
47. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S (2004) Molecular mechanisms of
mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem
73:39–85.
48. Reardon JT, Sancar A (2006) Purification and characterization of Escherichia coli and
human nucleotide excision repair enzyme systems. Methods Enzymol 408:189–213.
49. Liedert B, Pluim D, Schellens J, Thomale J (2006) Adduct-specific monoclonal antibo-
dies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei.
Nucleic Acids Res 34:e47.
Kang et al. PNAS ∣ March 16, 2010 ∣ vol. 107 ∣ no. 11 ∣ 4895
BI
O
CH
EM
IS
TR
Y
